Male hypogonadism is a condition in which the body is unable to produce sufficient amounts of testosterone, leading to various health problems such as decreased muscle mass, decreased libido, and erectile dysfunction. This condition affects a significant number of men worldwide and is commonly associated with aging. However, male hypogonadism can also be caused by other factors such as genetics, medications, and medical conditions. The market for male hypogonadism is expected to grow significantly in the coming years, driven by increasing awareness and advancements in treatment options. The Male Hypogonadism market was valued at USD 2.6 billion in 2021 and is projected to reach USD 3.7 billion by 2030, growing at a CAGR of 4.5% from 2022 to 2030.

Get PDF sample report with related graphs & charts (Pre & post COVID-19 impact analysis):

The increasing awareness of male hypogonadism among patients and healthcare professionals is one of the key drivers of the market. With the growing awareness of the condition and its associated health problems, more men are seeking medical help and diagnosis. This has led to an increase in the diagnosis and treatment of male hypogonadism, which is driving market growth.

Another driver of the Male Hypogonadism market is the advancements in treatment options. The development of new and effective treatment options such as testosterone replacement therapy (TRT) and gonadotropin-releasing hormone (GnRH) therapy is driving market growth. These treatments have been shown to be effective in improving the symptoms of male hypogonadism and are gaining popularity among patients and healthcare professionals.

One of the major restraints of the Male Hypogonadism market is the high cost of treatment. TRT and GnRH therapy can be expensive, which limits their adoption among patients. Additionally, the side effects associated with these treatments may also hinder market growth.

Speak to our analyst in case of queries before buying this report:

Major Market Players Profiled in the Male Hypogonadism Market Report include:

  • AbbVie
  • Antares Pharma, Inc.
  • Aytu BioScience, Inc.
  • Clarus Therapeutics, Inc.
  • Eli Lilly and Company
  • Endo Pharmaceuticals
  • Merck & Co. Inc.
  • Pharmacia & Upjohn Co. (Pfizer Inc.)
  • Teva Pharmaceutical Industries Ltd
  • Upsher-Smith Laboratories, LLC.
  • Other Market Participants

Ask for discount on this report:

Our 420+ Pages Report titled, Male Hypogonadism Market will include extensive information on the following pointers:

  • Global market size and forecast values (2015 – 2030), in terms of revenue (US$ Million) and volume (Kilotons) by segments/sub-segments
  • Split of the market revenue (US$ Million) and Volume (Kilotons) into all the relevant segments & sub-segments across all major regions/countries.
  • Years Considered (2015 – 2030)
    • (Historic Years: 2015 – 2020
    • Base Year: 2021
    • Forecast Years: 2022 – 2030)
  • Market determinants and Influencing Factors
  • Market Dynamics (Drivers, Restraints, Opportunities and Trends)
  • Analysis on Impact of Covid-19 on Global Male Hypogonadism Market
  • Macro-Economic and Micro-Economic Indicators
  • Porter’s Five Forces Analysis
  • Regulatory Landscape
  • PESTEL Analysis
  • Competitive Benchmarking: Global Presence and Growth Strategies
    • (Mergers and Acquisitions
    • Product Launches
    • Investments Trends
    • R&D Initiatives)
  • Market Share Analysis, 2021
  • Detailed profiles of major market participants operating in the market, encompassing information pertaining to Company Details, Company Overview, Product Offerings, Key Developments, Financial Analysis, SWOT Analysis and Business Strategies
  • Region specific report, including North America, Europe, Asia Pacific, Middle East & Africa and Latin America, can also be provided.
  • The reports can be provided in different languages including German, Korean, Arabic, Russian, French, Japanese, Spanish, Chinese and other languages.

Purchase the latest in-depth Global Male Hypogonadism Market Report @

Global Male Hypogonadism Market Segmentation:

By Type

  • Primary
  • Secondary

By Therapy

  • Testosterone replacement therapy
  • Gonadotropin-releasing hormones therapy

By Diagnosis

  • Hormone testing
  • Semen analysis
  • Pituitary imaging
  • Genetic studies
  • Testicular biopsy

By Region:

  • North America [U.S., Canada, Mexico]
  • Europe [Germany, UK, France, Italy, Rest of Europe]
  • Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
  • South America [Brazil, Argentina, Rest of Latin America]
  • Middle East & Africa [GCC, North Africa, South Africa, Rest of the Middle East and Africa]

Request for customization to meet your precise research requirements:

We appreciate your reading the article in its entirety. If you would like to know more about the Male Hypogonadism market, looking for customization, contact us. To achieve a full market reach of Male Hypogonadism, or explore more about opportunities reach our research analyst. Our team is available 24/7 to assist and support our customers through reliable research.

View our exclusive press releases on Industry Global News24 –

About Us:

Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization. From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:

Contact Name: Shreyas Tanna

Company: Absolute Markets Insights

Email Id:

Phone: IN +91-7400-24-24-24, US +1-510-420-1213


Leave a Reply

Your email address will not be published. Required fields are marked *